Obaldia 3rd N
Antimicrob Agents Chemother. 2024; 68(7):e0033824.
PMID: 38837364
PMC: 11232403.
DOI: 10.1128/aac.00338-24.
Watson D, Laing L, Petzer J, Wong H, Parkinson C, Wiesner L
Front Pharmacol. 2024; 14:1308400.
PMID: 38259296
PMC: 10800708.
DOI: 10.3389/fphar.2023.1308400.
Golenser J, Hunt N, Birman I, Jaffe C, Zech J, Mader K
Glob Chall. 2023; 7(12):2300030.
PMID: 38094863
PMC: 10714028.
DOI: 10.1002/gch2.202300030.
Beng T, Garcia J, Eichwald J, Borg C
RSC Adv. 2023; 13(21):14355-14360.
PMID: 37180005
PMC: 10171042.
DOI: 10.1039/d3ra01812a.
Newman D
Natl Sci Rev. 2022; 9(11):nwac206.
PMID: 36404871
PMC: 9668068.
DOI: 10.1093/nsr/nwac206.
Antimalarial and antitumour activities of the steroidal quinone-methide celastrol and its combinations with artemiside, artemisone and methylene blue.
Ng J, Han Y, Yang L, Birkholtz L, Coertzen D, Wong H
Front Pharmacol. 2022; 13:988748.
PMID: 36120293
PMC: 9479156.
DOI: 10.3389/fphar.2022.988748.
Synthesis and biological evaluation of novel artemisone-piperazine-tetronamide hybrids.
Wei M, Yu J, Liu X, Li X, Yang J, Zhang M
RSC Adv. 2022; 11(30):18333-18341.
PMID: 35480921
PMC: 9033422.
DOI: 10.1039/d1ra00750e.
The Artemiside-Artemisox-Artemisone-M1 Tetrad: Efficacies against Blood Stage Parasites, DMPK Properties, and the Case for Artemiside.
Gibhard L, Coertzen D, Reader J, van der Watt M, Birkholtz L, Wong H
Pharmaceutics. 2021; 13(12).
PMID: 34959347
PMC: 8704606.
DOI: 10.3390/pharmaceutics13122066.
A Drug Repurposing Approach for Antimalarials Interfering with SARS-CoV-2 Spike Protein Receptor Binding Domain (RBD) and Human Angiotensin-Converting Enzyme 2 (ACE2).
Coghi P, Yang L, Ng J, Haynes R, Memo M, Gianoncelli A
Pharmaceuticals (Basel). 2021; 14(10).
PMID: 34681178
PMC: 8537658.
DOI: 10.3390/ph14100954.
Liposomes for malaria management: the evolution from 1980 to 2020.
Memvanga P, Nkanga C
Malar J. 2021; 20(1):327.
PMID: 34315484
PMC: 8313885.
DOI: 10.1186/s12936-021-03858-0.
Toward New Transmission-Blocking Combination Therapies: Pharmacokinetics of 10-Amino-Artemisinins and 11-Aza-Artemisinin and Comparison with Dihydroartemisinin and Artemether.
Watson D, Laing L, Gibhard L, Wong H, Haynes R, Wiesner L
Antimicrob Agents Chemother. 2021; 65(8):e0099021.
PMID: 34097488
PMC: 8284440.
DOI: 10.1128/AAC.00990-21.
Small Molecules-Prospective Novel HCMV Inhibitors.
Bogner E, Egorova A, Makarov V
Viruses. 2021; 13(3).
PMID: 33809292
PMC: 8000834.
DOI: 10.3390/v13030474.
Efficient Treatment of Experimental Cerebral Malaria by an Artemisone-SMEDDS System: Impact of Application Route and Dosing Frequency.
Zech J, Salaymeh N, Hunt N, Mader K, Golenser J
Antimicrob Agents Chemother. 2021; 65(4).
PMID: 33558284
PMC: 8097435.
DOI: 10.1128/AAC.02106-20.
Anti-Melanoma Activities of Artemisone and Prenylated Amino-Artemisinins in Combination With Known Anticancer Drugs.
Wong H, Lewies A, Haigh M, Viljoen J, Wentzel J, Haynes R
Front Pharmacol. 2020; 11:558894.
PMID: 33117161
PMC: 7552967.
DOI: 10.3389/fphar.2020.558894.
Safety of Artemisinin Derivatives in the First Trimester of Pregnancy: A Controversial Story.
DAlessandro S, Menegola E, Parapini S, Taramelli D, Basilico N
Molecules. 2020; 25(15).
PMID: 32752056
PMC: 7435965.
DOI: 10.3390/molecules25153505.
Treatment of Experimental Cerebral Malaria by Slow Release of Artemisone From Injectable Pasty Formulation.
Golenser J, Salaymeh N, Higazi A, Alyan M, Daif M, Dzikowski R
Front Pharmacol. 2020; 11:846.
PMID: 32595499
PMC: 7303303.
DOI: 10.3389/fphar.2020.00846.
Oral Administration of Artemisone for the Treatment of Schistosomiasis: Formulation Challenges and In Vivo Efficacy.
Zech J, Gold D, Salaymeh N, Sasson N, Rabinowitch I, Golenser J
Pharmaceutics. 2020; 12(6).
PMID: 32503130
PMC: 7356104.
DOI: 10.3390/pharmaceutics12060509.
Late-Stage Diversification of Natural Products.
Hong B, Luo T, Lei X
ACS Cent Sci. 2020; 6(5):622-635.
PMID: 32490181
PMC: 7256965.
DOI: 10.1021/acscentsci.9b00916.
Quantum Chemical Lipophilicities of Antimalarial Drugs in Relation to Terminal Half-Life.
Alia J, Karl S, Kelly T
ACS Omega. 2020; 5(12):6500-6515.
PMID: 32258886
PMC: 7114756.
DOI: 10.1021/acsomega.9b04140.
Optimal 10-Aminoartemisinins With Potent Transmission-Blocking Capabilities for New Artemisinin Combination Therapies-Activities Against Blood Stage Including KI3 C580Y Mutants and Liver Stage Parasites.
Wong H, Padin-Irizarry V, van der Watt M, Reader J, Liebenberg W, Wiesner L
Front Chem. 2020; 7:901.
PMID: 31998692
PMC: 6967409.
DOI: 10.3389/fchem.2019.00901.
